- Licenses aim to accelerate drug discovery leading to development of new therapies
- PanCELLa agreement marks MilliporeSigma’s first CRISPR license for bioproduction
“MilliporeSigma’s latest CRISPR licenses are the impetus for drug discovery that promises to accelerate research leading to the development of new therapies,” said Chris Ross, interim CEO, MilliporeSigma. “We have been at the forefront of gene-editing innovation for 16 years and continue to work, both ethically and responsibly, with the global scientific community to solve problems by using our patented CRISPR technology.”….
to read the full article, please click here